Research Paper Volume 16, Issue 10 pp 8772—8809
Prediction of prognosis and immunotherapy efficacy based on metabolic landscape in lung adenocarcinoma by bulk, single-cell RNA sequencing and Mendelian randomization analyses
Figure 2. The metabolic heterogeneity of lung adenocarcinoma (LUAD). (A) The differences of 84 metabolic pathways scores between LUAD and normal tissues in TCGA. (B) An unsupervised consensus clustering according to 84 metabolic pathways scores in TCGA-LUAD samples. (C) Principal Component Analysis of cluster A and B of TCGA-LUAD. (D) The differences of 84 metabolic pathways scores between cluster A and cluster B. Pathological stage, sex, age, and survival status used as patients’ annotation. (E) The differences of 84 metabolic pathways scores among different cells by single-cell RNA sequencing (scRNA-seq) data. *P < 0.05, **P < 0.01, ***P < 0.001.